查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1562476

寡核苷酸合成市场规模、份额、成长分析、按产品、按应用、按最终用户、按地区 - 产业预测，2024-2031

Oligonucleotide Synthesis Market Size, Share, Growth Analysis, By Product, By Application, By End User, By Region - Industry Forecast 2024-2031
出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格
简介目录

寡核苷酸合成的全球市场规模预计从2023 年的73 亿美元成长到2022 年约60 亿美元，预测期内（2024-2031 年）复合年增长率为17.4%，到2031 年将达到26.3 亿美元。

由于研究、诊断、治疗和药物开发应用的不断扩大，寡核苷酸合成市场正在经历显着成长。寡核苷酸是合成的短 DNA 或 RNA 分子，用于基因测试、研究和法医学。基于寡核苷酸的疗法，特别是反义寡核苷酸（ASO）、小干扰RNA（siRNA）和适体的发展，为治疗各种遗传性疾病、癌症和感染疾病。此外，个人化医疗的兴起以及 CRISPR-Cas9 和其他基因编辑技术的出现正在推动对高品质寡核苷酸的需求。此外，寡核苷酸在 qPCR 和次世代定序(NGS) 等分子诊断中的不断扩大应用进一步推动了市场成长。由于其先进的医疗基础设施、大量的研发投资和强大的产业影响力，北美占据了最大的市场占有率。同时，由于医疗保健支出增加、生物技术产业扩张以及政府措施，预计亚太地区将经历最快的成长。然而，治疗性寡核苷酸的高成本、监管障碍以及对先进製造技术的需求等挑战在一定程度上限制了市场的成长。

目录

介绍

  • 研究目的
  • 定义
  • 市场范围

调查方法

  • 资讯采购
  • 二手资料来源和主要资料来源
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 市场概况展望
  • 供需趋势分析
  • 按细分市场的机会分析

市场动态及展望

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 波特的分析

主要市场考察

  • 市场生态系统
  • 风险分析
  • 创新矩阵
  • 主要投资分析
  • 关键成功因素
  • 竞争程度

寡核苷酸合成市场：副产品

  • 市场概况
  • 基于寡核苷酸的药物
    • 基于反义寡核苷酸的药物
    • 基于 siRNA 寡核苷酸的药物
    • 其他寡核苷酸药物
  • 合成寡核苷酸
    • 底漆
    • 探测
    • DNA寡核苷酸
    • RNA寡核苷酸
    • 其他合成寡核苷酸
    • 自订寡核苷酸
    • 预先设计的寡核苷酸
  • 试剂/耗材
  • 装置

寡核苷酸合成市场：依应用分类

  • 市场概况
  • 治疗用途
    • 疾病类型
    • 神经系统疾病
    • 罕见疾病
    • 其他疾病
  • 研究用途
    • PCR
    • 定序
    • 其他研究用途
  • 诊断用途

寡核苷酸合成市场：依最终用户分类

  • 市场概况
  • 医院
  • 製药和生物技术公司
  • 诊断实验室
  • 合约研究官（CRO）和首席行销长（CMO）
  • 学术研究所

按地区分類的寡核苷酸合成市场规模

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位（2023年）
  • 主要市场参与者所采取的策略
  • 近期市集活动
  • 主要企业市场占有率（2023年）

主要企业简介

  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Eurofins Scientific
  • Agilent Technologies, Inc.
  • Kaneka Corporation
  • Azenta, Inc.
  • Sarepta Therapeutics, Inc.
  • AstraZeneca
  • Astellas Pharma Inc.
  • Jazz Pharmaceuticals PLC
  • Nippon Shinyaku, Co. Ltd.（NS Pharma, Inc.）
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • OligoMaker ApS（Part of TAG Copenhagen A/S）
  • Biolegio BV
  • Biolytic Lab Performance, Inc.
  • Bio-Synthesis, Inc.
  • Creative Biogene
  • Reprocell, Inc.
简介目录
Product Code: SQMIG35H2107

Global Oligonucleotide Synthesis Market size was valued at around 6 billion in 2022 and is expected to rise from USD 7.3 billion in 2023 to reach a value of USD 26.3 billion by 2031, at a CAGR of 17.4% over the forecast period (2024-2031).

The Oligonucleotide Synthesis Market has been growing significantly due to its expanding applications in research, diagnostics, therapeutics, and drug development. Oligonucleotides are short DNA or RNA molecules that are synthesized for use in genetic testing, research, and forensics. The development of oligonucleotide-based therapeutics, particularly antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, has opened new avenues for treating various genetic disorders, cancers, and infectious diseases. Additionally, the rise in personalized medicine and the emergence of CRISPR-Cas9 and other gene-editing technologies are propelling the demand for high-quality oligonucleotides. Moreover, the expanding application of oligonucleotides in molecular diagnostics, such as qPCR and next-generation sequencing (NGS), further fuels market growth. North America holds the largest market share due to advanced healthcare infrastructure, substantial R&D investments, and strong industry presence. Meanwhile, Asia-Pacific is expected to witness the fastest growth due to increasing healthcare expenditures, expanding biotechnology sector, and rising government initiatives to develop healthcare research infrastructure. However, challenges such as high costs of therapeutic oligonucleotides, regulatory hurdles, and the need for sophisticated technologies in manufacturing are restraining the market growth to some extent.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oligonucleotide Synthesis Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oligonucleotide Synthesis Market Segmental Analysis

Global Oligonucleotide Synthesis Market is segmented by Product, Application, End User, and region. Based on Product, the market is segmented into Oligonucleotide-based Drugs (Antisense Oligonucleotide-based drug, siRNA oligonucleotide-based drug, Other oligonucleotide-based drug), Synthesized Oligonucleotides (Primers, Probes, DNA Oligos, RNA Oligos, Other Synthesized Oligos (Customized Oligos, Predesigned Oligos), Reagents & Consumables, and Equipment. Based on Application, the market is segmented into Therapeutic Applications (Disease Type (Neurological Disorders, Rare Diseases, Other Diseases), Research Applications (PCR, Sequencing, Other Research Applications), and Diagnostic Applications. Based on End User, the market is segmented into Hospitals, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, CROs and CMOs, Academic Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Oligonucleotide Synthesis Market

One of the primary drivers of the oligonucleotide synthesis market is the rising adoption of oligonucleotide-based therapeutics, particularly in the treatment of rare genetic disorders, cancers, and viral infections. Oligonucleotide therapeutics, such as ASOs and siRNAs, have gained significant attention due to their ability to target specific RNA molecules, allowing for highly targeted gene expression modulation. This specificity minimizes off-target effects and enhances the therapeutic index, making them highly desirable in personalized medicine. Additionally, advancements in delivery technologies, such as lipid nanoparticles and conjugation methods, have further enhanced the pharmacokinetic and pharmacodynamic properties of oligonucleotides, increasing their clinical efficacy. The FDA approval of drugs like Spinraza (nusinersen) for spinal muscular atrophy and Onpattro (patisiran) for polyneuropathy has further validated the therapeutic potential of oligonucleotides, encouraging biopharmaceutical companies to invest heavily in this promising field.

Restraints in the Global Oligonucleotide Synthesis Market

One of the significant restraints impacting the oligonucleotide synthesis market is the high cost associated with oligonucleotide therapeutics. The complexity involved in the chemical synthesis, purification, and scaling up of oligonucleotides leads to substantial production costs. These costs are often passed on to end users, resulting in expensive final products, which can limit accessibility, especially in developing regions with constrained healthcare budgets. Moreover, the development and production of oligonucleotide-based drugs require high levels of expertise, advanced technologies, and stringent regulatory approvals, which further increase the cost burden. The challenge is amplified by the need for specialized storage and delivery methods to maintain oligonucleotide stability and efficacy. These high costs pose a barrier for widespread adoption in clinical settings, slowing the overall market growth despite the potential benefits of oligonucleotide therapeutics.

Market Trends of the Global Oligonucleotide Synthesis Market

A significant trend shaping the oligonucleotide synthesis market is the rapid advancement in gene editing technologies, particularly CRISPR-Cas9 and related systems. These technologies have revolutionized genetic research by enabling precise, targeted alterations in DNA sequences, thereby enhancing the utility of oligonucleotides in gene modulation applications. Researchers are increasingly utilizing custom-synthesized oligonucleotides as guide RNAs (gRNAs) in CRISPR systems to target specific genes, paving the way for innovative therapeutic approaches to tackle previously untreatable genetic diseases. The integration of oligonucleotide synthesis with gene-editing technologies is not limited to therapeutic applications but also extends to functional genomics, agriculture, and synthetic biology. Companies are investing heavily in R&D to develop high-fidelity and efficient oligonucleotide synthesis platforms that cater to the growing demand for gene editing tools, thereby driving market growth and expanding the scope of genetic medicine.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Ecosystem of the Market
  • Risk Analysis
  • Innovation Matrix
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Oligonucleotide Synthesis Market by Product

  • Market Overview
  • Oligonucleotide-based Drugs
    • Antisense Oligonucleotide-based drug
    • siRNA oligonucleotide-based drug
    • Other oligonucleotide-based drug
  • Synthesized Oligonucleotides
    • Primers
    • Probes
    • DNA Oligos
    • RNA Oligos
    • Other Synthesized Oligos
    • Customized Oligos
    • Predesigned Oligos
  • Reagents & Consumables
  • Equipment

Oligonucleotide Synthesis Market by Application

  • Market Overview
  • Therapeutic Applications
    • Disease Type
    • Neurological Disorders
    • Rare Diseases
    • Other Diseases
  • Research Applications
    • PCR
    • Sequencing
    • Other Research Applications
  • Diagnostic Applications

Oligonucleotide Synthesis Market by End User

  • Market Overview
  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • CROs and CMOs
  • Academic Research Institutes

Oligonucleotide Synthesis Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Danaher Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eurofins Scientific
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agilent Technologies, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kaneka Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Azenta, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sarepta Therapeutics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Jazz Pharmaceuticals PLC
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nippon Shinyaku, Co. Ltd. (NS Pharma, Inc.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ionis Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • OligoMaker ApS (Part of TAG Copenhagen A/S)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biolegio BV
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biolytic Lab Performance, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Synthesis, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Creative Biogene
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Reprocell, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments